Operating Room Air Filtration/Sterilization
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04610294 |
Recruitment Status :
Recruiting
First Posted : October 30, 2020
Last Update Posted : July 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Non-cardiac Surgery | Device: Functioning Aerus air filtration/sterilization Device: Deactivated Aerus air filtration/sterilization |
Study Type : | Observational |
Estimated Enrollment : | 86639 participants |
Observational Model: | Case-Crossover |
Time Perspective: | Prospective |
Official Title: | Operating Room Air Filtration/Sterilization and Surgical Site Infection: A Randomized Multiple Cross-over Cluster Trial |
Actual Study Start Date : | May 1, 2021 |
Estimated Primary Completion Date : | January 2024 |
Estimated Study Completion Date : | June 2024 |

Group/Cohort | Intervention/treatment |
---|---|
Aerus air sterilization
Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
|
Device: Functioning Aerus air filtration/sterilization
Two units of Aerus air sterilization system will be used in each operating room, and each will be set to "high." Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. |
Conventional air handling
Only routine room air filtration will be used in an operation room.
|
Device: Deactivated Aerus air filtration/sterilization
Two units of Aerus air sterilization system will be used in each operating room, and each will be set to "high." Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the "run" lights. |
- Composite outcome of postoperative complications [ Time Frame: 30 days after surgery ]A composite of mortality, major surgical site infection, and healing-related wound complications
- Serious surgical site infection [ Time Frame: 30 days after surgery ]Deep or organ-space surgical site infection will be evaluated by analysis of International Classification of Disease revision 10 (ICD-10) diagnosis codes
- Cost-of-care [ Time Frame: 30 days after surgery ]Our economic analysis will estimate the cost-effectiveness ratio, defined as the difference in average total hospital costs divided by the difference in the proportion with any of the components of the composite, and expressed as average cost per 1 percent improvement in the composite outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- All patients in designated adult operating rooms
- American Society of Anesthesiologists physical status 1-4.
- Surgery lasting at least 1 hour.
Exclusion Criteria:
- patients with present-on-admission infections

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04610294
Contact: Roberta Johnson | 216-444-9950 | johnsor13@ccf.org | |
Contact: Mauro Bravo, MD | 216-636-9449 | bravom2@ccf.org |
United States, Ohio | |
Cleveland Clinic | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Roberta Johnson 216-444-9950 johnsor13@ccf.org | |
Contact: Mauro Bravo, MD 216-636-9449 bravom2@ccf.org | |
Principal Investigator: Daniel I Sessler, MD |
Principal Investigator: | Daniel I Sessler, MD | The Cleveland Clinic |
Responsible Party: | The Cleveland Clinic |
ClinicalTrials.gov Identifier: | NCT04610294 |
Other Study ID Numbers: |
20-656 |
First Posted: | October 30, 2020 Key Record Dates |
Last Update Posted: | July 13, 2021 |
Last Verified: | July 2021 |
Studies a U.S. FDA-regulated Device Product: | No |